The results of multiplex MethyLight analysis indicated that the traditional assay failed to identify a significant proportion of cancer patients, likely due to the reduced PCR efficiency or, in the case of CDO1, nonspecific interactions of primers with other target amplicons (Figure4a).[15a] Clinical sensitivity and specificity are used to characterize the clinical performance of tests, which refer to the ability of assays to correctly identify patients with cancer or without cancer, respectively. This evidence concerns the gene CDO1 and cancer.